The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
A phase I study of ombrabulin (O) combined with bevacizumab (B) in patients with advanced solid tumors.
Michael Ong
No relevant relationships to disclose
Gianluca Del Conte
No relevant relationships to disclose
Rastislav Bahleda
No relevant relationships to disclose
Joaquin Mateo
No relevant relationships to disclose
Silvia Damian
No relevant relationships to disclose
Antonella Perotti
No relevant relationships to disclose
Nathalie Lassau
No relevant relationships to disclose
Françoise Farace
No relevant relationships to disclose
Jimena Lovosgaldeano
No relevant relationships to disclose
Nina Tunariu
No relevant relationships to disclose
Marie Hospitel
Employment or Leadership Position - Sanofi
Paola Mariani
No relevant relationships to disclose
Patrick Cohen
Employment or Leadership Position - Sanofi
Stock Ownership - Sanofi
Giuseppe Capri
No relevant relationships to disclose
Jean-Charles Soria
Consultant or Advisory Role - Sanofi
Honoraria - Sanofi
Luca Gianni
No relevant relationships to disclose
L Rhoda Molife
No relevant relationships to disclose
Cristiana Sessa
Consultant or Advisory Role - Sanofi
Research Funding - Sanofi